CPTx Appoints David Maier to Lead gxstrands Business Unit

CPTx, a pioneer in the development and manufacturing of novel genetic medicines built with single-stranded DNA (ssDNA), has appointed David Maier to lead the contract development and manufacturing (CDMO) business unit focused on ssDNA supply called gxstrands.

Maier will build strategic partnerships and expand capacity and service breadth to meet growing demand for custom ssDNA manufacturing solutions enabling next-generation genetic medicines.

“Over the past decade, our team has developed and refined scalable ssDNA manufacturing processes,” said Hendrik Dietz, PhD, founder of CPTx. “We are excited to have David leading gxstrands, which now leverages this foundation to deliver high-fidelity, configurable ssDNA to customers worldwide. CPTx will remain focused on advancing novel ssDNA-powered in vivo gene therapies through both our internal in vivo CAR-T pipeline and collaborations with external partners.”

Experience

Maier comes to gxstrands with more than 20 years of biopharmaceutical executive and commercial experience. He has led a global business unit at West Pharmaceutical Services, developed new biologics CDMO offerings at Lonza, and held various leadership, transactional, and strategic positions at Novartis. He began his career as an officer in the U.S. Marine Corps and in management consulting at L.E.K. Maier has an MBA from Cornell’s Johnson School and a bachelor’s degree from Harvard University.

“Our unique fermentation-based upstream and precision downstream purification process deliver high-fidelity ssDNA with customizable lengths and diverse topologies at scalable yields,” said Maier. “We are building a best-in-class CDMO partner for the future of gene and cell therapy and other genetic medicines applications, and I am excited to help grow this business globally.”